Literature DB >> 11790328

Effects of octopamine on lipolysis, glucose transport and amine oxidation in mammalian fat cells.

E Fontana1, N Morin, D Prévot, C Carpéné.   

Abstract

Octopamine is known to exert adrenergic effects in mammals although specific octopamine receptors have been cloned only in invertebrates. It has been shown that octopamine can stimulate alpha(2)-adrenoceptors (ARs) in Chinese hamster ovary cells transfected with human alpha(2)-ARs. More recently, we reported that octopamine stimulates lipolysis through beta(3)-rather than beta(1)-or beta(2)-AR activation in white adipocytes from different mammalian species. The present study was thus undertaken to further characterize the adrenergic properties of octopamine. For this purpose, several biological processes known to be regulated by adrenergic stimulation were studied in response to octopamine, noradrenaline, adrenaline and tyramine in white adipocytes from different mammals. First, octopamine was fully lipolytic in garden dormouse and Siberian hamster while tyramine was ineffective. Although being around one hundred-fold less potent that noradrenaline, octopamine was slightly more potent in these hibernators known for their high sensitivity to beta(3)-AR agonists than in rat and chiefly more active than in human adipocytes known for their limited responses to beta(3)-AR agonists. Second, octopamine reduced insulin-dependent glucose transport in rat fat cells, a response also observed with noradrenaline and selective beta(3)-AR agonists but not with beta(1)-or beta(2)-agonists. Third, human adipocytes, which endogenously express a high level of alpha(2)-ARs, exhibited a clear alpha(2)-adrenergic antilipolytic response to adrenaline but not to octopamine. Moreover, octopamine exhibited only a very weak affinity for the alpha(2A)-ARs labeled by [3H]RX821002 in human adipocyte membranes. In Syrian hamster adipocytes, which also possess alpha(2)-ARs, octopamine induced only a weak antilipolysis. Finally, octopamine was a substrate of fat cell amine oxidases, with an apparent affinity similar to that of noradrenaline. All these results demonstrate that octopamine, tyramine noradrenaline and adrenaline can be degraded by adipocyte amine oxidases. However these biogenic amines interact differently with adipocyte adrenoceptors: tyramine is inactive, adrenaline and noradrenaline activate both beta- and alpha(2)-ARs while octopamine activates only beta(3)-ARs and is devoid of alpha(2)-adrenergic agonism. Thus, octopamine could be considered as an endogenous selective beta(3)-AR agonist.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11790328     DOI: 10.1016/s0742-8413(99)00086-9

Source DB:  PubMed          Journal:  Comp Biochem Physiol C Toxicol Pharmacol        ISSN: 1532-0456            Impact factor:   3.228


  4 in total

1.  Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development.

Authors:  Jolene Zheng; Joseph R Vasselli; Jason F King; Michael L King; Wenqian We; Zachary Fitzpatrick; William D Johnson; John W Finley; Roy J Martin; Michael J Keenan; Frederic M Enright; Frank L Greenway
Journal:  Am J Ther       Date:  2016 Nov/Dec       Impact factor: 2.688

2.  Combinatorial synthesis of unsymmetrical secondary amines. Application to arylethanolamines, arylpropanolamines and aryloxypropanolamines.

Authors:  S K Rastogi; P Gupta; T Srinivasan; B Kundu
Journal:  Mol Divers       Date:  2000       Impact factor: 2.943

3.  Caffeine exposure induces browning features in adipose tissue in vitro and in vivo.

Authors:  Ksenija Velickovic; Declan Wayne; Hilda Anaid Lugo Leija; Ian Bloor; David E Morris; James Law; Helen Budge; Harold Sacks; Michael E Symonds; Virginie Sottile
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

4.  Effects of ingesting JavaFit Energy Extreme functional coffee on aerobic and anaerobic fitness markers in recreationally-active coffee consumers.

Authors:  Michael D Roberts; Lemuel W Taylor; Jennifer A Wismann; Colin D Wilborn; Richard B Kreider; Darryn S Willoughby
Journal:  J Int Soc Sports Nutr       Date:  2007-12-08       Impact factor: 5.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.